Treatment of Indolent Systemic Mastocytosis With PA101

Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study With PA101 in Patients With Indolent Systemic Mastocytosis

Sponsors

Lead Sponsor: Patara Pharma

Source Patara Pharma
Brief Summary

This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in adult patients with indolent systemic mastocytosis (ISM). The purpose of the study is to determine the efficacy and safety profile of PA101 delivered via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using standard treatments.

Detailed Description

The symptom scores for determining eligibility will be established during the 2-week Run-in Period using eDiary and the eligible patients will be randomly allocated in a 2:1 ratio to one of two treatment cohorts at the baseline visit. In Cohort 1 (n=24), patients will receive inhaled 40 mg PA101 three times daily and inhaled placebo three times daily via eFlow for 6 weeks each in a double-blind, 2-period crossover fashion with a 4-week washout period between the treatment periods. In Cohort 2 (n=12), patients will receive inhaled 40 mg PA101 three times daily via eFlow and oral cromolyn sodium 200 mg four times daily for 6 weeks each in an open label, 2-period crossover fashion with a 4-week washout period between the treatment periods. Patients will be allowed to use the same daily doses of pre-randomization H1 and H2 antihistamines as well as the same daily doses of any other allowed medications during each treatment period. Visits during each treatment period will occur at the baseline Visit, and at the end of Weeks 1, 2, 4, and 6. Blood and urine samples will be collected to test for various biomarkers. In a subset of patients, additional clinical assessments of the skin will be performed and blood samples will be collected for pharmacokinetic assessments. Clinical safety assessments will be performed in all patients at the start and end of each treatment period.

Overall Status Completed
Start Date 2015-06-01
Completion Date 2016-06-01
Primary Completion Date 2016-03-01
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Overall symptom score 6 weeks
Secondary Outcome
Measure Time Frame
Disease specific quality of life (QoL) 6 weeks
Patient Global Impression of Change (PGIC) scale 6 weeks
Enrollment 41
Condition
Intervention

Intervention Type: Drug

Intervention Name: PA101

Description: 40 mg PA101 administered via inhalation three times daily for 6 weeks

Arm Group Label: PA101

Intervention Type: Drug

Intervention Name: Placebo

Description: matching placebo administered via inhalation three times daily for 6 weeks

Arm Group Label: Placebo

Eligibility

Criteria:

Inclusion Criteria: - Diagnosis of indolent systemic mastocytosis (ISM) according to the WHO criteria and the consensus proposal (2001) - Experiencing at least one predefined qualifying symptom in at least two organ systems within 3 months of Screening despite the use of H1 and/or H2 antihistamines and other anti-mediator therapy - Experiencing symptoms with a severity score of at least 4 for at least 7 out of 14 days during the Run-in period with at least one predefined qualifying symptom each from at least two organ systems, despite the use of H1 and/or H2 antihistamines and/or other anti-mediator therapy - Willing and able to use an eDiary device daily for the duration of the study - Completed at least 5 eDiary reports during each of two consecutive weeks of the Run-in period - Willing and able to provide written informed consent prior to any study procedures Exclusion Criteria: - Advanced systemic mastocytosis (i.e., aggressive systemic mastocytosis [ASM], mast cell leukemia [MCL], or systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease [SM-AHNMD] ) - Current or recent history of clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, malignant, or other illnesses that could put the patient at risk or compromise the quality of the study data as determined by the Investigator - Use of oral cromolyn sodium within 6 weeks of Screening - History of systemic corticosteroid, immunosuppressive, or anti-IgE monoclonal antibody therapy (e.g., omalizumab) within 6 months of Screening - History of anaphylaxis requiring systemic treatment (i.e., corticosteroid or epinephrine) within 12 months of Screening - Upper or lower respiratory tract infection within 4 weeks of Screening - History of malignancy within the last 5 years, except basal cell carcinoma or cervix carcinoma in situ - Major surgery within 6 months of Screening - Current or recent history (within 12 months) of excessive use or abuse of alcohol - Current or recent history (within 12 months) of abusing legal drugs or use of illegal drugs or substances - Pregnant or breastfeeding females, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study - Participation in any other investigational drug study within 4 weeks of Screening - History of hypersensitivity or intolerance to aerosol medications or cromolyn sodium

Gender:

All

Minimum Age:

18 Years

Maximum Age:

75 Years

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Frank Siebenhaar, MD Principal Investigator Charite University, Berlin, Germany
Location
Facility:
Hopital Necker - Enfants Malades | Paris, France
Charité - Universitätsmedizin Berlin | Berlin, Germany
Klinikum Darmstadt | Darmstadt, Germany
University Medical Center Mainz | Mainz, Germany
Technical University München | Munich, Germany
University of Salerno | Salerno, Italy
University Medical Center of Groningen | Groningen, Netherlands
Hospital Universitario de Fuenlabrada | Madrid, Spain
Location Countries

France

Germany

Italy

Netherlands

Spain

Verification Date

2016-09-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: PA101

Type: Experimental

Description: PA101, 40 mg administered via inhalation three times daily for 6 weeks

Label: Placebo

Type: Placebo Comparator

Description: Placebo, administered via inhalation three times daily for 6 weeks

Study Design Info

Allocation: Randomized

Intervention Model: Crossover Assignment

Primary Purpose: Treatment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News